trending Market Intelligence /marketintelligence/en/news-insights/trending/WHxbHZasMmFixHK-fbk2Eg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Morphic Holding plans IPO on Nasdaq


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Morphic Holding plans IPO on Nasdaq

Morphic Holding Inc. is planning an IPO of its common stock on the Nasdaq Global Market.

The Waltham, Mass.-based biopharmaceutical company is focused on developing oral integrin therapies, with its early experimental drugs aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis.

Morphic plans to list its common stock on the Nasdaq Global Market under the symbol MORF.

The company plans to use the proceeds from the offering to fund further development of its experimental drugs and use any remaining amounts to fund working capital and general corporate purposes.

Jefferies LLC, Cowen and Co. LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC are listed as underwriters for the IPO.